SOZO® Digital Health Platform Receives FDA Clearance for Sarcopenia Risk Assessment

RegulatoryapprovedSOZO Digital Health PlatformPositive

AI Analysis

Summary

ImpediMed's SOZO Digital Health Platform received FDA clearance for an expanded indication to assess sarcopenia risk in cancer care, enabling earlier detection and intervention from a single rapid scan.

Outcome Details

FDA clearance for expanded indication for sarcopenia risk assessment

Importance:7/10

Sentiment:

0.75

FDA clearanceRegulatory approvalMedical deviceSarcopeniaOncologyDigital health

Related Companies

$MDCE $HIT $RTSL

Read the original article

Published by PR Newswire Biotech on August 18, 2026 4:15 PM

Read Original